| Biotechnology feed | All feeds
plans on raising about $272.4 million through an initial public offering and said it will use the proceeds to develop a drug for irritable bowel syndrome.
The company, based in Cambridge, Mass., is offering just under 16.7... Bioscience Technology Online: Jan 29 2010 3:58PM Matching: amitiza Find similar documents
(NASDAQ:SCMP), today presented additional clinical data for lubiprostone (Amitiza) at GASTRO 2009 UEGF/WCOG, the joint meeting of the United... Pharma Live: Nov 25 2009 10:25PM Matching: amitiza Find similar documents
(NASDAQ: SCMP), today announced that Swissmedic, the Swiss Agency for Therapeutic Products, has granted a marketing authorization for Amitiza (lubiprostone) 24 microgram (mcg)... Pharma Live: Nov 19 2009 11:51PM Matching: amitiza Find similar documents
Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.
All rights reserved. All other trademarks recognized. Copyright 1997-2009 - BioPortfolio Limited.
